Project Grant R01AI189789
Award Date
1/2/25
Completion Date
12/31/29
Dollars Obligated
$808K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award, valued at $220,096 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the mechanisms of tetrodotoxin (TTX) biosynthesis in microbial symbionts. The project, conducted by Michigan State University, leverages the discovery of TTX-producing bacteria on the skin of newts to identify the genetic basis of TTX production. The research approaches...
This Project Grant award, totaling $616,816, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support structural and functional studies of the ORFX-type progenitor toxin complex (PTC) associated with botulinum neurotoxins (BoNTs) produced by Clostridium bacteria. The key objectives are to: 1) characterize the mechanisms underlying the assembly of the ORFX/P47 complex, 2)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,660,212 in funding to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for research on "Armed Nanobodies as Anti-Infectives and Anti-Tumor Agents." The key products and services to be delivered under this award include: Developing a nanobody that recognizes...
This federal Project Grant award, valued at $639,084 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the heterogeneity of naïve CD8 T cells and its impact on immune responses and T cell homeostasis. The research will investigate both mouse and human naïve CD8 T cells, with the goal of developing strategies to induce protective naïve CD8 T cell immunity...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,569 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant will fund research to characterize and optimize a novel genetic vaccine platform called PARVAX, with the goal of increasing its clinical acceptance and application for pandemic preparedness. Key objectives include investigating the mechanism behind the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $154,568.00 to support research to uncover the molecular mechanisms by which the innate immune effector TRIM56 restricts a broad range of viruses, with a focus on HIV-1. The research aims to (1) investigate how TRIM56 directly or indirectly recognizes viral RNA, and (2) determine the ubiquitination targets of TRIM56...
This Project Grant award for $256,995.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support research at Tufts University School of Medicine to quantitatively link the intracellular traits of the Legionella pneumophila pathogen, such as fitness and iron starvation response, to host cell mutations identified through CRISPR/Cas9 editing. This innovative optical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
This $3,559,162 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to modulate indoleamines and optimize immunity in the setting of Mycobacterium tuberculosis (MTB)/HIV co-infection. The project, which runs from June 2024 to April 2029, aims to use macaque models of MTB/SIV co-infection to study the role of the IDO pathway in inhibiting effective immunity to TB and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College, doing business as Harvard Medical School, to investigate the molecular mechanisms underlying the activation and regulation of essential bacterial cell wall synthases. The $637,729 award, granted on December 13, 2024, will fund research aimed at developing a detailed mechanistic understanding...